Henlius Forges Ahead With US PD-1 Plans Despite Peers' Setbacks

Bridging Study Planned

 
• By Dexter Jie Yan

The latest step by the Chinese drug maker to support its international ambitions is a bridging study in the US, which will evaluate its PD-1 contender serplulimab against Roche’s PD-L1-targeted Tecentriq.

US PD-1 market
Like its compatriots, Henlius can't resist lure of the US market • Source: Shutterstock

More from China

More from Focus On Asia